Biopharma
Alnylam Pharmaceuticals
RNA interference medicines
About Alnylam Pharmaceuticals
Alnylam is a biopharmaceutical company specialising in medicines based on RNA interference.
French resources cover hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1. The company explains its scientific platform and the use of RNA interference in medicine development.
Official sources
- Alnylam® Pharmaceuticals — Chef de file de l'ARNi thérapeutique | France
- Alnylam France — page officielle, Alnylam France SAS, RCS 818575730
Information checked 10 November 2026
Logo sourceAssociated catalogue products
1 reference
These products are linked to this organisation in the catalogue as a laboratory or supplier. Refer to each product page for its documented manufacturer or operator. Purchasing terms and ordering are available through your professional account.
Your professional shop
Open the shop to sign in, view the terms available to your account and place your order.
Open the shop